CL2020002915A1 - Composiciones para el tratamiento de condiciones de la piel - Google Patents

Composiciones para el tratamiento de condiciones de la piel

Info

Publication number
CL2020002915A1
CL2020002915A1 CL2020002915A CL2020002915A CL2020002915A1 CL 2020002915 A1 CL2020002915 A1 CL 2020002915A1 CL 2020002915 A CL2020002915 A CL 2020002915A CL 2020002915 A CL2020002915 A CL 2020002915A CL 2020002915 A1 CL2020002915 A1 CL 2020002915A1
Authority
CL
Chile
Prior art keywords
compositions
treatment
skin
metabolites
skin conditions
Prior art date
Application number
CL2020002915A
Other languages
English (en)
Inventor
Paul Wagner
Original Assignee
Forte Subsidiary Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forte Subsidiary Inc filed Critical Forte Subsidiary Inc
Publication of CL2020002915A1 publication Critical patent/CL2020002915A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen métodos y composiciones para el tratamiento de las condiciones de la piel asociadas a la disbiosis. En el presente documento se describe además el uso de metabolitos para el tratamiento de la microbiota desregulada en un Sujeto. Dichos metabolitos pueden ser producidos por microorganismos presentes en mayor abundancia en la piel de los Sujetos sanos en comparación con la piel de un Sujeto que tiene disbiosis de la piel. Además, las composiciones y métodos proporcionados en este documento describen el uso de Metabolitos como parte de una terapia de combinación.
CL2020002915A 2018-05-11 2020-11-10 Composiciones para el tratamiento de condiciones de la piel CL2020002915A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670341P 2018-05-11 2018-05-11
US201862703737P 2018-07-26 2018-07-26

Publications (1)

Publication Number Publication Date
CL2020002915A1 true CL2020002915A1 (es) 2021-04-30

Family

ID=68465006

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002915A CL2020002915A1 (es) 2018-05-11 2020-11-10 Composiciones para el tratamiento de condiciones de la piel

Country Status (13)

Country Link
US (2) US10973841B2 (es)
EP (1) EP3790563A4 (es)
JP (1) JP2021523900A (es)
KR (1) KR20210013080A (es)
CN (1) CN113194969A (es)
BR (1) BR112020023050A2 (es)
CA (1) CA3099903A1 (es)
CL (1) CL2020002915A1 (es)
GB (1) GB2588721A (es)
MX (1) MX2020012018A (es)
SG (1) SG11202011188SA (es)
WO (1) WO2019217203A1 (es)
ZA (1) ZA202007055B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310626A (zh) 2016-04-19 2019-02-05 美利坚合众国,由健康及人类服务部部长代表 革兰氏阴性种治疗特应性皮炎的用途
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
JP7829286B2 (ja) * 2020-05-29 2026-03-13 大王製紙株式会社 使い捨て着用物品
EP4000688B1 (en) 2020-11-19 2025-11-05 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of trenbolone acetate having a definite particle size distribution
EP4001289B1 (en) 2020-11-19 2023-05-03 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of trenbolone and/or trenbolone acetate
EP4001288B1 (en) 2020-11-19 2025-05-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of trenbolone acetate having a definite particle size distribution and a irregular hexagon plates crystal habit
CN116139163B (zh) * 2023-03-22 2023-09-05 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种粘液玫瑰单胞菌胞外多糖在制备用于缓解特应性皮炎的药物上的应用
CN115927128B (zh) * 2023-03-10 2023-05-09 广州优科生物科技有限公司 一种透明颤菌发酵产物及其制备方法与应用
CN116531310B (zh) * 2023-05-18 2023-12-22 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 粘液玫瑰单胞菌及其胞外多糖在制备用于改善皮肤状况产品中的应用
CN118987049A (zh) * 2023-05-17 2024-11-22 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 粘液玫瑰单胞菌活菌制剂及胞外多糖在制备用于缓解uvb导致的皮肤损伤的药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4829000A (en) 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
DK0727979T3 (da) 1993-10-22 2001-10-01 Smithkline Beecham Corp Nyt præparat
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6974585B2 (en) 2001-08-01 2005-12-13 Medlogic Global Limited Durable multi-component antibiotic formulation for topical use
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
DE10158712A1 (de) 2001-11-29 2003-06-26 Umwelttechnik Georg Fritzmeier Zusammensetzung zur Behandlung der Hautoberfläche
ZA200604768B (en) * 2003-11-11 2007-10-31 Veckis Ind Ltd Disinfecting composition and methods of making and using same
ATE511848T1 (de) 2004-08-25 2011-06-15 Us Gov Health & Human Serv Lebendige mikrobielle mikrobizide
JP2006131622A (ja) 2004-10-05 2006-05-25 Genichiro Soma 薬剤
KR20070091613A (ko) 2004-11-08 2007-09-11 그렌마크 파머수티칼스 엘티디. 항여드름 화합물 및 항생제 화합물을 함유하는 국소적 제약조성물
EP1736537A1 (en) 2005-06-22 2006-12-27 OrganoBalance GmbH Methods and means for protecting the skin against pathogenic microorganisms
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
JP6159084B2 (ja) 2009-06-30 2017-07-05 デルマン バイオメディシン カンパニー リミテッド 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
EP2465507A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
US20140065209A1 (en) 2011-05-03 2014-03-06 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
KR20210100224A (ko) 2014-04-15 2021-08-13 에이오바이오미 엘엘씨 암모니아-산화 니트로소모나스 유트로파 균주 d23
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US9526201B2 (en) 2015-01-05 2016-12-27 Cnh Industrial America Llc Twin-row planter with tandem driven seed meters
EP3285872A4 (en) * 2015-04-20 2019-02-20 S-Biomedic NV METHOD AND COMPOSITIONS FOR CHANGING THE COMPOSITION OF SKIN MICROBIOMA WITH COMPLEX MIXTURES OF BACTERIAL BARS
CN109069878A (zh) * 2015-07-02 2018-12-21 Ao生物医学有限责任公司 微生物群系相容性化妆品
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
CN109310626A (zh) 2016-04-19 2019-02-05 美利坚合众国,由健康及人类服务部部长代表 革兰氏阴性种治疗特应性皮炎的用途
US9889165B2 (en) * 2016-04-21 2018-02-13 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
WO2018049556A1 (en) * 2016-09-13 2018-03-22 The Procter & Gamble Company Methods of increasing microbial diversity of a skin microbiota
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
CA3106976A1 (en) 2018-07-23 2020-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis

Also Published As

Publication number Publication date
JP2021523900A (ja) 2021-09-09
GB2588721A (en) 2021-05-05
CN113194969A (zh) 2021-07-30
ZA202007055B (en) 2022-08-31
CA3099903A1 (en) 2019-11-14
GB202017977D0 (en) 2020-12-30
WO2019217203A1 (en) 2019-11-14
BR112020023050A2 (pt) 2021-03-16
US20210186998A1 (en) 2021-06-24
US20190343856A1 (en) 2019-11-14
SG11202011188SA (en) 2020-12-30
MX2020012018A (es) 2021-03-02
EP3790563A1 (en) 2021-03-17
EP3790563A4 (en) 2022-03-23
KR20210013080A (ko) 2021-02-03
US10973841B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
CL2021000415A1 (es) Vesículas derivadas de lactobacillus paracasei y uso de las mismas
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
ECSP20013332A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
CL2016002992A1 (es) Combinación, composición y método de administración de la combinación o composición a animales
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
NI202000014A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
MX2024012807A (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
MX2017015293A (es) Composicion para tratar lesiones tisulares.
MX2018016003A (es) Tratamiento combinado para lesiones neurológicas.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX395106B (es) Celulas t alogenicas específicas de wt1 y usos de las mismas.
BR112016012435A2 (pt) Vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso